Neurology News

WEST PALM BEACH, Fla. — Inclusion of underrepresented racial and ethnic groups, along with older patients, patients from rural areas and uninsured patients in multiple sclerosis-targeted clinical trials is likely to improve outcomes, according to a speaker.

Two separate studies found no evidence to link anomalous health incidents with MRI-based biomarkers of disease or adverse results of neuropsychological testing among U.S. government staff, their families and matched controls.

The FDA has approved Duvyzat for the treatment of Duchenne muscular dystrophy among patients aged 6 years and older, according to a press release.

A recent NIH study of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome suggests that the condition is a “distinct entity,” with somatic and cognitive issues that are centrally mediated.

Focused ultrasound could provide clinicians a safer alternative in diagnosing, monitoring and treating patients with brain tumors compared with biopsy, according to findings published in npj Precision Oncology.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.

WEST PALM BEACH, Fla. — Treatment with clemastine fumarate was linked to accelerated disease and disability progression due to pyroptosis in a small cohort of individuals with multiple sclerosis, according to a presenter at ACTRIMS 2024.

When I first entered the medical profession more than 30 years ago, I was taken by the amount of trash that was produced in the emergency department where I volunteered.

While psychedelic use may be associated with fewer psychotic symptoms among adolescents, the link between psychedelics and manic symptoms appears to be associated with genetic vulnerability to schizophrenia or bipolar disorder, data show.

The FDA has approved breakthrough device designation for a novel neuroimmune modulation platform for those with relapsing-remitting multiple sclerosis, according to the manufacturer.